{
  "extraction_metadata": {
    "timestamp": "2025-10-01T17:02:21.233193",
    "source_type": "hta_submission",
    "indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
    "total_countries": 10,
    "total_picos": 30,
    "temperature": 0.3
  },
  "picos_by_country": {
    "AT": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "AT",
      "PICOs": [
        {
          "Population": "adults with HCC in Barcelona Clinic Liver Cancer (BCLC) stage B or C who did not receive any prior systemic therapy for the advanced or inoperable disease. Hepatic cirrhosis of any aetiology was not an exclusion criterion. Patients in BCLC stage B had to be ineligible for transarterial chemoembolization (TACE). Further inclusion criteria were Child-Pugh stage A and an Eastern Cooperative Oncology Group – Performance Status (ECOG-PS) score of 0 or 1.",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "sorafenib",
          "Outcomes": ""
        },
        {
          "Population": "Adult patients with advanced or inoperable hepatocellular carcinoma (HCC) who have not yet received systemic therapy: with Child-Pugh A or no hepatic cirrhosis",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "sorafenib",
          "Outcomes": ""
        },
        {
          "Population": "Adult patients with advanced or inoperable hepatocellular carcinoma (HCC) who have not yet received systemic therapy: with Child-Pugh B",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "BSC",
          "Outcomes": ""
        },
        {
          "Population": "Child-Pugh A patients with unresectable HCC",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "placebo",
          "Outcomes": ""
        },
        {
          "Population": "adult patients with advanced (unresectable or metastatic) HCC",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "placebo or placebo-based (without sorafenib) therapy",
          "Outcomes": ""
        },
        {
          "Population": "hepatocellular carcinoma patients",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "Placebo",
          "Outcomes": ""
        }
      ],
      "ChunksUsed": 30,
      "ContextTokens": 11148
    },
    "DE": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "DE",
      "PICOs": [
        {
          "Population": "Adult patients with advanced or inoperable hepatocellular carcinoma (HCC) who have not yet received systemic therapy:  with Child-Pugh A or no hepatic cirrhosis",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "Sorafenib",
          "Outcomes": ""
        },
        {
          "Population": "Adult patients with advanced or inoperable hepatocellular carcinoma (HCC) who have not yet received systemic therapy:  with Child-Pugh B",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "BSC",
          "Outcomes": ""
        },
        {
          "Population": "Child-Pugh A patients with unresectable HCC",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "placebo",
          "Outcomes": ""
        },
        {
          "Population": "adult patients with advanced (unresectable or metastatic) HCC",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "placebo or placebo-based (without sorafenib) therapy",
          "Outcomes": ""
        },
        {
          "Population": "hepatocellular carcinoma patients",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "Placebo",
          "Outcomes": ""
        }
      ],
      "ChunksUsed": 30,
      "ContextTokens": 11131
    },
    "DK": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "DK",
      "PICOs": [
        {
          "Population": "Adult patients with advanced HCC and adult patients with inoperable HCC not previously treated systemically.",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "sorafenib (Nexavar)",
          "Outcomes": ""
        }
      ],
      "ChunksUsed": 30,
      "ContextTokens": 10938
    },
    "EN": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "EN",
      "PICOs": [
        {
          "Population": "adults with advanced or unresectable hepatocellular carcinoma (HCC) who have not had previous systemic treatment, only if they have Child-Pugh grade A liver impairment and an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "sorafenib",
          "Outcomes": ""
        },
        {
          "Population": "adults with advanced or unresectable hepatocellular carcinoma (HCC) who have not had previous systemic treatment, only if they have Child-Pugh grade A liver impairment and an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "lenvatinib",
          "Outcomes": ""
        }
      ],
      "ChunksUsed": 30,
      "ContextTokens": 10505
    },
    "ES": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "ES",
      "PICOs": [
        {
          "Population": "patients aged 18 years or older and diagnosed with locally advanced or metastatic and/ or unresectable HCC with histological/ cytological confirmation or clinical features consistent with the American Association for the Study of the Liver (AASLD) criteria in cirrhotic patients",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "sorafenib",
          "Outcomes": ""
        },
        {
          "Population": "patients with advanced and/ or unresectable hepatocellular carcinoma who have not received prior systemic therapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "sorafenib",
          "Outcomes": ""
        },
        {
          "Population": "patients with advanced or unresectable hepatocellular carcinoma",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "lenvatinib",
          "Outcomes": ""
        },
        {
          "Population": "patients with advanced or unresectable hepatocellular carcinoma",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "placebo",
          "Outcomes": ""
        }
      ],
      "ChunksUsed": 20,
      "ContextTokens": 7274
    },
    "FR": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "FR",
      "PICOs": [
        {
          "Population": "adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "sorafenib",
          "Outcomes": ""
        },
        {
          "Population": "patients with advanced or unresectable hepatocellular carcinoma (stage BCLC B or C) who have not received prior systemic therapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "sorafenib",
          "Outcomes": ""
        },
        {
          "Population": "patients with advanced or unresectable hepatocellular carcinoma with preserved general condition (ECOG ≤ 2) and preserved hepatic function (Child-Pugh A) who have not received prior systemic therapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "sorafenib",
          "Outcomes": ""
        },
        {
          "Population": "patients classified as Stage B (not eligible for chemoembolism) or C by the BCLC (Barcelona Clinic Liver Cancer) classification, Child-Pugh score A, ECOG score of 0 to 1, who have not received prior systemic therapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "sorafenib",
          "Outcomes": ""
        }
      ],
      "ChunksUsed": 27,
      "ContextTokens": 8952
    },
    "NL": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "NL",
      "PICOs": [
        {
          "Population": "patients with advanced hepatocellular carcinoma",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "placebo",
          "Outcomes": ""
        },
        {
          "Population": "patients with hepatocellular carcinoma for whom initiation of curative treatment or (continuation of) locoregional or local palliative treatment is not possible or considered medically inappropriate (hepatocell carcinomas)",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "best care regimen available",
          "Outcomes": ""
        }
      ],
      "ChunksUsed": 15,
      "ContextTokens": 4512
    },
    "PO": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "PO",
      "PICOs": [],
      "ChunksUsed": 30,
      "ContextTokens": 9885
    },
    "PT": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "PT",
      "PICOs": [
        {
          "Population": "patients with unresectable HCC",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "sorafenib",
          "Outcomes": ""
        },
        {
          "Population": "adult patients with advanced or non-resectable hepatocellular carcinoma (HCC) and who have not received any previous systemic therapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "sorafenib",
          "Outcomes": ""
        }
      ],
      "ChunksUsed": 10,
      "ContextTokens": 3267
    },
    "SE": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "SE",
      "PICOs": [
        {
          "Population": "first-line treatment of adult patients with advanced or non-resectable hepatocellular carcinoma",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "atezolizumab plus bevacizumab",
          "Outcomes": ""
        },
        {
          "Population": "first-line treatment of adult patients with advanced or non-resectable hepatocellular carcinoma",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "sorafenib",
          "Outcomes": ""
        },
        {
          "Population": "first-line treatment of adult patients with advanced or non-resectable hepatocellular carcinoma",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "lenvatinib",
          "Outcomes": ""
        },
        {
          "Population": "patients whose HCC has non-viral etiology",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "atezolizumab plus bevacizumab",
          "Outcomes": ""
        }
      ],
      "ChunksUsed": 30,
      "ContextTokens": 11945
    }
  }
}